Request Demo

Last update 20 Jun 2026

Amoxicillin Trihydrate

Last update 20 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryAmoxicillin Trihydrate is a small molecule drug that belongs to the group of cell wall inhibitors, used as an antibiotic to treat bacterial infections such as bronchitis, pneumonia, urinary tract infections, and strep throat. Amoxicillin works by inhibiting the growth of bacteria by preventing the formation of their cell walls. The drug is available in various forms, including tablets, capsules, and oral suspension, and has been marketed under different brand names since its FDA approval in 1974. While generally safe, some individuals may experience side effects such as diarrhea, nausea, and skin rash. Those allergic to penicillin may also experience an allergic reaction to Amoxicillin. As with any medication, patients should follow the prescribed dosage and consult their healthcare provider if symptoms persist or worsen.

Drug Type

Small molecule drug

Synonyms

6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid, AmoxiciIIin, Amoxicilin

+ [56]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesRespiratory Diseases+ [2]

Active Indication

Endocarditis, BacterialGenitourinary tract infectionGonorrhea+ [4]

Inactive Indication

PharyngitisPulmonary TuberculosisTonsillitis

Originator Organization

GSK Plc

Active Organization

Meiji Seika Pharma Co., Ltd.

Sandoz Pty Ltd.

LTL Pharma Co., Ltd.

+ [3]

Inactive Organization

GSK Plc

Pragma Pharmaceuticals LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (18 Jan 1974),

Tonsillitis

Regulation-

Structure/Sequence

Molecular FormulaC16H25N3O8S

InChIKeyMQXQVCLAUDMCEF-CWLIKTDRSA-N

CAS Registry61336-70-7

1,007

Clinical Trials associated with Amoxicillin Trihydrate

NCT07485010

/ Not yet recruitingPhase 2IIT

A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.

Start Date01 Apr 2027

Sponsor / Collaborator

The University of Queensland

[+1]

NCT07457385

/ Not yet recruitingPhase 4IIT

Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs. Benzathine in Neonates With Possible Congenital Syphilis

The Investigator hypothesize that the treatment efficacy will be similar in both study arms. Secondary outcomes and endpoints will characterize safety by comparing adverse events (AEs), tolerability, and adherence to therapy in each arm.
This is a Phase 4, open-label, multicenter trial designed to evaluate the efficacy of a single injected dose of intramuscular (IM) BPG (Arm 1) compared to oral amoxicillin administered twice daily (BID) for 10 days (Arm 2). The study will involve infants aged ≤ 30 days old with suspected untreated syphilis. The trial will be conducted at 12 sites across the U.S., enrolling approximately 374 participants.
Upon randomization, participants will undergo baseline study sample collection (blood, oropharyngeal, and nasal mucosal swabs for PCR testing) and then receive either treatment with oral amoxicillin or IM BPG, both with directly observed therapy. The participant enrolled in the optional pharmacokinetic (PK) sub-study will have additional blood samples collected for PK analysis within the first 24-48 hours after treatment. Participants will be discharged from the hospital following routine procedures, with the oral amoxicillin dosing continued at home (BID) by the caregiver.

Start Date01 Nov 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT07275580

/ Not yet recruitingPhase 4IIT

Effectiveness of Short-Course Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases

This randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether single-dose amoxicillin prophylaxis administered prior to simple tooth extraction reduces postoperative infection rates in immunosuppressed patients with autoimmune rheumatic diseases (ARDs).
Although antibiotic prophylaxis is not recommended for healthy individuals undergoing simple extractions, immunosuppressed ARD patients frequently receive antibiotics despite limited evidence supporting this practice.
Secondary objectives include assessing infection severity, postoperative complications, and the impact of ARD diagnosis and immunosuppressive treatment on infection risk.

Start Date01 Jun 2026

Sponsor / Collaborator

University of Sao Paulo General Hospital

[+1]

100 Clinical Results associated with Amoxicillin Trihydrate

100 Translational Medicine associated with Amoxicillin Trihydrate

100 Patents (Medical) associated with Amoxicillin Trihydrate

26,481

Literatures (Medical) associated with Amoxicillin Trihydrate

01 Nov 2026·Biomaterials advances

An injectable, rapidly photo-crosslinkable hybrid hydrogel with temporally coordinated release and attenuation of inflammatory activation for potential extraction socket management

Article

Author: Huang, Xiaojing ; Huang, Yan ; Lei, Huaxiang ; Zhang, Shujun ; Wang, Xiuqing ; Li, Luhui ; Wang, Yumin ; Huang, Jing ; Zeng, Yu ; Chen, Yuemin ; Wu, Jingxuan

Tooth extraction sockets represent a particularly demanding wound environment, characterized by spatial confinement, high moisture, continuous mechanical disturbance, and exposure to a dense oral microbiota. Effective healing requires localized therapeutic strategies that can be stably retained at the wound site while delivering stage-specific interventions in a temporally coordinated manner. In this study, we developed an injectable Pluronic F127 diacrylate (PF127DA)/methacrylated hyaluronic acid (HAMA) hybrid hydrogel as a locally retained and clinically practical therapeutic platform for potential extraction socket management. The hydrogel exhibits favorable injectability, rapid photo-induced gelation within 3 s, robust tissue stability, tissue adhesion, and controllable degradation, enabling stable localization within extraction sockets. As a multifunctional carrier, it supports the temporally coordinated release of amoxicillin, ropivacaine, and fibroblast growth factor-2 (FGF-2), providing early antibacterial protection, sustained local analgesia, and prolonged pro-regenerative factor availability in accordance with wound healing progression. In vitro studies demonstrated that the hydrogel system exhibited effective antibacterial activity and a sustained ropivacaine release profile. Importantly, the hydrogel system also showed attenuation of excessive pro-inflammatory activation together with a modest shift toward repair-associated macrophage features. Overall, this study presents a material-mediated strategy that integrates robust tissue stability, temporally coordinated multi-drug delivery, and inflammatory attenuation within a single injectable hydrogel platform, offering a potential approach for the localized management of extraction sockets and other clinically challenging wounds.

01 Oct 2026·TISSUE & CELL

Vitamin D3 in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway

Article

Author: Xin, Yi ; Zhao, Shuai ; Wang, Wenxiao ; Shan, Chengyan ; Zhong, Yaoyao ; Wan, Daihong

BACKGROUND:

Helicobacter pylori (H. pylori) is a primary pathogen associated with gastritis, peptic ulcers, and gastric cancer. Current eradication therapies are increasingly compromised by antibiotic resistance. Vitamin D₃ (VD₃) has shown potential as an adjunct therapy, yet its underlying mechanism remains unclear.

OBJECTIVE:

This study evaluated the efficacy of VD₃ combined with triple therapy on H. pylori eradication in mice, assessing pathological changes, infection and inflammation levels and epithelial cell death; furthermore, it explored the mechanism of the synergistic effect.

METHODS:

An in vivo model was inoculated with H. pylori to establish in mice. After four weeks, mice were treated with VD₃, triple therapy, quadruple therapy (omeprazole, amoxicillin, clarithromycin and bismuth potassium citrate), or their combinations for another four weeks. Hematoxylin and Eosin (H&E) staining, quantitative real-time PCR, colony formation, immunoblotting, enzyme-linked immunosorbent assay (ELISA), TUNEL staining, and caspase activity assays were used to evaluate the effect of VD₃.

RESULTS:

Compared to triple therapy alone, the combination of VD₃ and triple therapy reduced gastritis severity, H. pylori 16S rDNA expression, and bacterial colony counts in infected mice. It also decreased mRNA and protein levels of inflammatory cytokines IL-1β, IL-6, and TNF-α, reduced gastric epithelial cell apoptosis, and suppressed caspase-3/6/9 activities. VD₃ treatment further enhanced c-Raf, MEK, and ERK phosphorylation in gastric tissues. Importantly, the ERK inhibitor U0126 abrogated the therapeutic benefits of VD₃ combined with triple therapy, leading to increased gastritis severity, H. pylori 16S rDNA expression, bacterial colony counts, and caspase activity.

CONCLUSION:

Vitamin D3 synergizes with triple therapy to eradicate H. pylori infection by exhibiting antibacterial, anti-inflammatory, and cytoprotective effects through regulation of the c-Raf/MEK/ERK signaling pathway.

01 Sep 2026·Exploratory research in clinical and social pharmacy

Feasibility, fidelity and initial effects of an app-based service for short-term antibiotic therapy: A pilot study in a primary care setting

Article

Author: Sutter, Vanessa ; Arnet, Isabelle ; Messner, Kirstin ; Allemann, Samuel

Background:

Short-term antibiotic treatments show medication non-adherence rates around 40%, limiting therapy success and increasing risk for recurring infections. Smartphone applications offer simple solutions to support patients' medication adherence.

Objective:

To evaluate service and trial feasibility of a smartphone-based adherence support delivered by community pharmacists and to explore initial effects.

Methods:

We conducted a cluster-randomized pilot trial. Community pharmacies recruited eligible patients with newly prescribed amoxicillin/clavulanic acid therapy when dispensing the prescription. Participants used an app to confirm medication intakes. The intervention group received intake reminders and text messages. We evaluated feasibility and fidelity based on data quality, participant satisfaction, and extent to which service activities were delivered as planned. For exploratory analyses, we used the Mann-Whitney U test, and calculated effect sizes.

Results:

Fifty-seven community pharmacies and 34 patients participated in the study (17 per group). Twenty-nine participants (85%) fully completed the study. Twenty-one participants (62%) used and returned the symptom diary. For 30 participants (88%), the app was installed correctly and twenty-five (83%) participants consistently used the app. We observed small, non-significant effects for taking adherence (r = 0.158) and timing adherence (r = 0.147), and small-medium (r = 0.294) for dosing adherence.

Conclusion:

This study demonstrated feasibility and fidelity of a smartphone-based therapy support in the community pharmacy setting. Trends suggest a potential improvement in adherence rates through smartphone reminders and text messages. These findings highlight the need for a fully powered trial.

310

News (Medical) associated with Amoxicillin Trihydrate

18 Jun 2026

·www.prnewswire.com

RedHill Biopharma Announces Up To $19.4 Million Private Placement

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants in a private placement. The Series A-1 warrants have an exercise price of $0.86 per ADS, are exercisable immediately and have a term of five years following the Effectiveness Date (as defined below), and the Series A-2 warrants have an exercise price of $0.70 per ADS, are exercisable immediately and have a term of 18 months following the Effectiveness Date. The private placement is expected to close on June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A-1 warrants and the series A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use a portion of the net proceeds to support a potential strategic product acquisition and the balance for working capital, research and development and general corporate purposes. No definitive acquisition agreement has been executed, and any such transaction would remain subject to completion of definitive documentation, financing and other customary conditions. There can be no assurance that any such transaction will be completed. The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the ordinary shares of the Company represented by ADSs underlying the warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the private placement and ordinary shares of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the "Effectiveness Date"). This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia ®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with U.S. government and academic collaborations intended for medical countermeasure development including for Ebola virus disease, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases. More information about the Company is available at / X.com/RedHillBio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, the potential exercise of the series warrants and potential proceeds therefrom, potential acquisition of strategic products, statements regarding the potential submission of Talicia® for UK Marketing Authorisation and any approval thereof and statements regarding the potential effects of Talicia® in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may not recover all or any of awards granted by the New York Supreme Court; the risk that opaganib does not receive a priority review voucher, marketing exclusivity or accelerated development and review times; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) the Company's ability to collect on its judgment against Kukbo; (xiii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiv) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xv) competition from other companies and technologies within the Company's industry; and (xvi) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: Financials [1]Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo - Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma [email protected] SOURCE RedHill Biopharma Ltd. 21% more press release views with Request a Demo

Clinical ResultPhase 2

18 Jun 2026

·allsci.com

RedHill raises USD 19.4m to fund acquisition hunt amid cash crunch

Israel-based RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a private placement of ADSs and accompanying warrants with potential gross proceeds of up to USD 19.4 million, structured to support a possible strategic product acquisition and sustain pipeline and commercial operations. The transaction follows a period of sustained cash pressure — RedHill reported a cash balance of USD 4.1 million at year-end 2025 — and reflects continued reliance on equity capital markets since the 2023 divestiture of Movantik. The offering comprises 8,571,429 ADSs at USD 0.70 per ADS, generating USD 6 million in upfront gross proceeds before placement agent fees, and two warrant tranches that if fully exercised would yield up to approximately USD 13.4 million in additional proceeds. Company overview and pipeline RedHill is a specialty biopharmaceutical company with dual headquarters in Tel Aviv, Israel and Raleigh, North Carolina, focused on gastrointestinal diseases, infectious diseases, and oncology. Its commercial asset, Talicia (omeprazole magnesium, amoxicillin and rifabutin), is the FDA-approved leading branded H. pylori therapy prescribed by US gastroenterologists, now co-commercialized through Talicia Holdings Inc., a joint venture with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill retains a 70% interest in the venture. The lead pipeline asset is opaganib (ABC294640), an oral, first-in-class sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity currently in Phase II paired with Bayer’s darolutamide in metastatic castrate-resistant prostate cancer, among others. RHB-102 (Bekinda), a once-daily bimodal extended-release ondansetron formulation, is currently Phase II stage targeting GLP-1/GIP receptor agonist-associated GI side effects. And RHB-204, a next-generation fixed-dose combination antibiotic targeting MAP-positive Crohn’s disease, is advancing toward a planned Phase II study following positive FDA feedback on its approval pathway. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

08 Jun 2026

·www.prnewswire.com

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has commenced recognition and enforcement proceedings in Korea in respect of the New York Supreme Court's final judgment in favor of RedHill against Kukbo Co. Ltd ("Kukbo"), totaling approximately $10.9 million, and that Kukbo has now been served in those proceedings. In November 2025, the New York Supreme Court judgment on the principal award became final and eligible for enforcement and foreign recognition. The award to RedHill of legal fees and expenses is now also final following Kukbo's failure to perfect its appeal by the applicable deadline in March 2026. No further appeals are permissible with respect to either judgment. The Court awarded approximately $10.9 million in total to RedHill, comprised of the main judgment of approximately $8.9 million, and the award for legal fees and expenses of approximately $1.95 million, each including the principal amounts and accrued 9% statutory interest to date, which continues to accrue. RedHill had also previously secured a Korean court attachment grant against Kukbo aimed at preventing Kukbo from disposing of assets prior to judgment enforcement. Recognition and enforcement efforts are ongoing. Following service of the complaint in Korea, the Company now awaits Kukbo's response in the Korean proceeding and the further scheduling of the matter by the Korean court. No assurances can be provided regarding the timing of any recovery or the amount that may be recovered, including whether the Company will recover all or any portion of the awarded amounts. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases. Visit / X.com/RedHillBio for more information about the Company Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential for the Company to succeed in its enforcement action against Kukbo and recovery any or all of the awards granted by the New York Supreme Court. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may not recover all or any of awards granted by the New York Supreme Court; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) the Company's ability to collect on its judgment against Kukbo; (xiii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiv) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xv) competition from other companies and technologies within the Company's industry; and (xvi) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: Corporate [1] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo - SOURCE RedHill Biopharma Ltd. 21% more press release views with Request a Demo

Phase 2Clinical ResultPhase 3

100 Deals associated with Amoxicillin Trihydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00229	Amoxicillin Trihydrate	J01CA04	DB01060

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Endocarditis, Bacterial	Australia	Sandoz Pty Ltd.	22 May 2008
Genitourinary tract infection	Australia	Sandoz Pty Ltd.	22 May 2008
Gonorrhea	Australia	Sandoz Pty Ltd.	22 May 2008
Respiratory Tract Infections	Australia	Sandoz Pty Ltd.	22 May 2008
Skin and skin structure infections	Australia	Sandoz Pty Ltd.	22 May 2008
Pharyngitis	United States	Pragma Pharmaceuticals LLC	23 Jan 2008
Bacterial Infections	United States	USAntibiotics	21 Oct 1980
Infectious Diseases	Japan	LTL Pharma Co., Ltd.	06 Sep 1974
Infectious Diseases	Japan	Sandoz AG	06 Sep 1974
Tonsillitis	United States	GSK Plc	18 Jan 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Tuberculosis	Phase 2	South Africa	GSK Plc	01 Sep 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05345457 (CTgov)	Phase 4	Preterm Premature Rupture of the Membranes \| Obstetric Labor, Premature	1	Amoxicillin Pill+Azithromycin Pill (Antibiotics)	sxzziqwgtn(grzseqigje) = mszhpphsmj fhosdktsig (uwzccaazcc, gqcngqehol - vtnxjtdxtu) View more	-	18 Jun 2026
				antibiotics (No Antibiotics)	sxzziqwgtn(grzseqigje) = pzojrwvghr fhosdktsig (uwzccaazcc, lyjythpuub - sgiwqqroyz) View more
NCT05156437 (OPTIMAL, CTgov)	Phase 4	Endocarditis	5	Cefalexin+Levofloxacin+Amoxycillin+Oxacillin+Ceftriaxone+Dicloxacillin+Rifampicin+Ampicillin+Linezolid+Daptomycin+Vancomycin (Group I (Experimental))	nxlyliqhpy(fkuxlqghuh) = elcfmhzhlb jgzasyehyw (afqvirpmud, fkhlcoddgw - jhvhmgiksj) View more	-	05 May 2026
				Oxacillin+Ceftriaxone+Ampicillin+Daptomycin+Vancomycin (Group II (Control Group))	nxlyliqhpy(fkuxlqghuh) = oikuasknfp jgzasyehyw (afqvirpmud, vxxbzuzgmd - nvbwpqmyta) View more
NCT05834036 (CTgov)	Phase 4	Enterocolitis	10	Amoxicillin Oral Capsule	kcbfedclmz(uykaruftsp) = ivwmywwsjh azjpagvjiw (diblmyeogs, 0) View more	-	12 Mar 2026
AAAAI2026	Not Applicable	Allergy to penicillin	96	Oral amoxicillin challenges	svaknyujyq(rvzzkbqbmr) = dyhmpucwqu tgzyuntsyb (vhdrmrqvat ) View more	Positive	27 Feb 2026
AAAAI2026	Not Applicable	Allergy to penicillin	112	Penicillin (Penicillin Allergy Evaluation)	kyqafhgyoc(rqopkuzfqw) = lsanqlceyq thostranql (vzwoimsknw )	Positive	27 Feb 2026
NCT05664685 (Pubmed \| Lancet Reg Health Am)	Phase 4	Helicobacter pylori infection First line	127	Esomeprazole + Amoxicillin + Metronidazole + Bismuth subsalicylate	ikenflbclk(aidpohbyhu) = bwmldwskzi ckpafnzaeo (xexcvycxty, 86 - 99) View more	Positive	01 Jan 2026
				Omeprazole + Amoxicillin + Clarithromycin	ikenflbclk(aidpohbyhu) = dfkpumgoxk ckpafnzaeo (xexcvycxty, 70 - 89) View more
NCT05828758 (AmoxENI study, Pubmed \| J Pediatr Gastroenterol Nutr)	Phase 2/3	-	90	Amoxicillin	wgmdulelyd(gqgkhbmvwz) = yunpbvnfog prlnxypsrw (ffickuhnrx ) View more	Positive	01 Sep 2025
				Placebo	wgmdulelyd(gqgkhbmvwz) = mtamovcnkp prlnxypsrw (ffickuhnrx ) View more
NCT05977868 (COPAT, CTgov)	Phase 4	Bone and joint infections \| Genitourinary tract infection \| Infection of digestive system ... View more	94	cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+linezolid+amoxicillin-clavulanate+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental))	gbfowyiwyb = ikugbdtjhd jdjilhypwr (pxxkzdhrdp, ryoebdnbfi - ndfsrvfmcj) View more	-	26 Aug 2025
				cefazolin+ceftazidime-avibactam+dalbavancin+ampicillin-sulbactam+ceftaroline+ceftazidime+Ampicillin+cefepime+daptomycin+ertapenem (Group 2 (Control))	gbfowyiwyb = ecytsupksd jdjilhypwr (pxxkzdhrdp, lmreqsjfqg - bbqrvijbgj) View more
NCT06168084 (not provided, Pubmed \| United European Gastroenterol J)	Phase 4	Helicobacter pylori infection	688	Vonoprazan and High-Dose Amoxicillin (VHA) dual therapy	bzkhfhqbvn(xbvgmwkfqn) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) xswwgmrccy (ahqdcbnxza )	Positive	21 Jun 2025
				Tetracycline- and Furazolidone-based Bismuth-Containing Quadruple Therapy (TFEB)
NCT05649540 (Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	900	High-dose amoxicillin (HVA)	zmfpdppwqx(poihfuhevo) = iiyzuoolgv pnulpehubu (hucbbyhpni )	Positive	01 May 2025
				Medium-dose amoxicillin (MVA)	zmfpdppwqx(poihfuhevo) = xfsqbnohrx pnulpehubu (hucbbyhpni )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis